GlassScriptPhysician profile
Ryland E Melford
NPI 1598874869
$9,779.31
in general payments reported to CMS, 2019-2025
38 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,756 · 2020: $1,147 · 2021: $1,967 · 2022: $1,522 · 2023: $1,165 · 2024: $764 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $2,770.44 | 2019-2025 | Orsiro Mission |
| Boston Scientific Corporation | $818.08 | 2019-2024 | Watchman Access System, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $707.32 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $668.24 | 2019-2023 | Lifevest |
| Impulse Dynamics (USA) INC. | $530.71 | 2022-2023 | Optimizer |
| Amgen INC. | $483.98 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $379.44 | 2019-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $371.17 | 2019-2024 | |
| Astellas Pharma US INC | $339.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $336.02 | 2019-2022 | |
| Abbott Laboratories | $249.73 | 2019-2024 | Jot Dx, Amplatzer Amulet, Confirm Rx |
| Pfizer INC. | $239.18 | 2019-2025 | |
| Esperion Therapeutics, INC. | $193.67 | 2021-2025 | Nexletol, Nexlizet |
| Cvrx, INC. | $175.47 | 2021-2023 | Barostim Neo System |
| Scpharmaceuticals INC. | $175.38 | 2023-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryland Melford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.